Projected Out-of-Pocket Savings of the Medicare Part D $2 Drug List Model
- Hernandez, Inmaculada PharmD; PhD
- Gabriel, Nico MA
- Pathak, Yuvraj PhD
- Hansen, Ryan N. PharmD; PhD
- Sullivan, Sean D. BScPharm; PhD
- Fendrick, A. Mark MD
1Division of Clinical Pharmacy, University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla
2West Health Policy Center, Washington, DC
3The CHOICE Institute, School of Pharmacy, University of Washington, Seattle
4Department of Internal Medicine, University of Michigan, Ann Arbor
Article Information
Accepted for Publication: February 11, 2025.
Published Online: March 24, 2025. doi:10.1001/jama.2025.2028
Corresponding Author: Inmaculada Hernandez, PharmD, PhD, Division of Clinical Pharmacy, University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, 9500 Gilman Dr, Room 224, La Jolla, CA 92093 ([email protected]).
Author Contributions: Mr Gabriel had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Hernandez, Pathak, Hansen, Sullivan, Fendrick.
Acquisition, analysis, or interpretation of data: Hernandez, Gabriel, Pathak, Hansen, Fendrick.
Drafting of the manuscript: Hernandez, Gabriel, Pathak, Sullivan, Fendrick.
Critical review of the manuscript for important intellectual content: Pathak, Hansen, Fendrick.
Statistical analysis: Gabriel.
Obtained funding: Hernandez.
Administrative, technical, or material support: Hernandez, Hansen, Sullivan.
Supervision: Sullivan, Fendrick.
Conflict of Interest Disclosures: Dr Hansen reported being a partner at Kelley-Ross Pharmacy Group and president and chairman of the board of Compliant Pharmacy Alliance Cooperative. Dr Sullivan reported serving as a consultant to AbbVie, Neurocrine, Pfizer, Sanofi, and Takeda. Dr Fendrick reported serving as a consultant to AbbVie, Centivo, the Community Oncology Association, EmblemHealth, the Employee Benefits Research Institute, Exact Sciences, GRAIL, Health at Scale Technologies (equity interest), HealthCorum, the Hopewell Fund, Hygieia, Johnson & Johnson, Medtronic, MedZed, Merck, MotherGoose (equity interest), Phathom Pharmaceuticals, Proton Intelligence, Sempre Health (equity interest), Silver Fern HealthCare (equity interest), the US Department of Defense, the Virginia Center for Health Innovation, the Washington Health Benefit Exchange, Wellth (equity interest), the Yale New Haven Health System, and Zansors (equity interest). Dr Fendrick also reported receipt of research funding from Arnold Ventures, the State of Michigan, the Centers for Medicare & Medicaid Services, the West Health Policy Center, the Agency for Healthcare Research and Quality, the National Pharmaceutical Council, the Patient-Centered Outcomes Research Institute, the Pharmaceutical Research and Manufacturers of America, and the Robert Wood Johnson Foundation and holding outside positions as co–editor in chief of The American Journal of Managed Care, as past member of the Medicare Evidence Development and Coverage Advisory Committee, and as partner at VBID Health LLC. No other disclosures were reported.
Funding/Support: This work was funded by the West Health Policy Center.
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 2.
Received December 09, 2024
Accepted February 11, 2025
